Loading...
Loading...
SYRS| Name | Value |
|---|---|
| Revenues | 3.8M |
| Cost of Revenue | 0.6M |
| Gross Profit | 3.1M |
| Operating Expense | 38.4M |
| Operating I/L | -34.6M |
| Other Income/Expense | -5.5M |
| Interest Income | 1.6M |
| Pretax | -40.1M |
| Income Tax Expense | -3.3M |
| Net Income/Loss | -40.1M |
Syros Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development of treatments for cancer and monogenic diseases, with a focus on gene control medicines. The company's revenue is generated through the development and commercialization of its lead product candidates, including Tamibarotene, a selective retinoic acid receptor alpha agonist, SY-2101, a novel oral form of arsenic trioxide, and SY-5609, a cyclin-dependent kinase 7 inhibitor. Additionally, Syros has established research collaborations and option agreements with industry partners to identify therapeutic targets, further contributing to its revenue stream.
